No Yes Ok

Archive

« Older Entries Newer Entries »

Kreatech signs supply agreement with lung cancer mutation consortium Thursday, March 7th, 2013
Kreatech to supply REPEAT-FREE™ DNA FISH probes for U.S. National Lung Study Durham, NC – March 7, 2013 – KREATECH, Inc., the US subsidiary of KREATECH Diagnostics (Amsterdam, The Netherlands), announced they [...]
Prosensa Receives Rare Disease Company Award from EURORDIS Wednesday, February 27th, 2013
Leiden, The Netherlands – 27 February 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, received the ‘Company Award’ at the EUROR [...]
Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™ Tuesday, February 26th, 2013
Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Healt [...]
Okairos initiates Phase I clinical trial evaluating vaccine against RSV infections Monday, February 25th, 2013
Basel, Switzerland – 25 February 2013 – Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in inf [...]
Activaero initiates proof of concept trial with Lasag in severe influenza Tuesday, February 12th, 2013
Gemünden/Wohra, Germany, February 12, 2013: Activaero GmbH, the therapeutic area specialist for respiratory diseases, today announced that the first patients have been enrolled in an international proof of concept tr [...]
Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs Thursday, February 7th, 2013
Leiden, The Netherlands – 7 February 2013 – Prosensa Therapeutics, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced the appointment of Larr [...]
Merus Achieves Milestone with Novartis Option Fund Thursday, February 7th, 2013
Company Reaches Milestone in Biclonics™ Program Partnered with Novartis Utrecht, The Netherlands, February 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, toda [...]
4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets Tuesday, January 29th, 2013
Basel, Switzerland and New York, NY, 29 Jan, 2013: 4-Antibody AG and the Ludwig Institute for Cancer Research (the Ludwig Institute) today announced the signing of a multi-target R&D collaboration with Recepta Biopharma [...]
Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio Tuesday, January 29th, 2013
Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designat [...]
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™ Thursday, January 24th, 2013
Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has received a Notice of Allowance for its [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Kreatech signs supply agreement with lung cancer mutation consortium Thursday, March 7th, 2013
Kreatech to supply REPEAT-FREE™ DNA FISH probes for U.S. National Lung Study Durham, NC – March 7, 2013 – KREATECH, Inc., the US subsidiary of KREATECH Diagnostics (Amsterdam, The Netherlands), announced they [...]
Prosensa Receives Rare Disease Company Award from EURORDIS Wednesday, February 27th, 2013
Leiden, The Netherlands – 27 February 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, received the ‘Company Award’ at the EUROR [...]
Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™ Tuesday, February 26th, 2013
Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Healt [...]
Okairos initiates Phase I clinical trial evaluating vaccine against RSV infections Monday, February 25th, 2013
Basel, Switzerland – 25 February 2013 – Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in inf [...]
Activaero initiates proof of concept trial with Lasag in severe influenza Tuesday, February 12th, 2013
Gemünden/Wohra, Germany, February 12, 2013: Activaero GmbH, the therapeutic area specialist for respiratory diseases, today announced that the first patients have been enrolled in an international proof of concept tr [...]
Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs Thursday, February 7th, 2013
Leiden, The Netherlands – 7 February 2013 – Prosensa Therapeutics, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced the appointment of Larr [...]
Merus Achieves Milestone with Novartis Option Fund Thursday, February 7th, 2013
Company Reaches Milestone in Biclonics™ Program Partnered with Novartis Utrecht, The Netherlands, February 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, toda [...]
4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets Tuesday, January 29th, 2013
Basel, Switzerland and New York, NY, 29 Jan, 2013: 4-Antibody AG and the Ludwig Institute for Cancer Research (the Ludwig Institute) today announced the signing of a multi-target R&D collaboration with Recepta Biopharma [...]
Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio Tuesday, January 29th, 2013
Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designat [...]
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™ Thursday, January 24th, 2013
Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has received a Notice of Allowance for its [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund